of pituitary tumors characterized as grossly-enlarged pituitary masses with diffuse hyperplasia but no adenomatous foci. These tumors result from chronic stimulation of PRL secretion and lactotroph proliferation [5] . The development of estrogen-induced PRLsecreting pituitary tumors involves both hypothalamic and pituitary mechanisms. At the hypothalamic level, estrogen-induced PRL-secreting tumors are associated with a reduced synthesis and secretion of dopamine [6] [7] [8] , a potent inhibitor of lactotrophs [9] , or damage of tuberoinfundibular dopaminergic neurons [10, 11] . At the pituitary level, several molecules are implicated in the development of estrogen-induced pituitary tumors including galanin [12] , vasoactive intestinal peptide [13] , transforming growth factor-β1 [14] , pituitary tumor transforming gene product [15] , and bone Wendell et al. [24] reported that the Wistar-Kyoto (WKY) rat strain, an inbred, normotensive control for the spontaneously hypertensive rat, was as insensitive to estrogen-induced pituitary tumors as the Brown Norway rat. The present study therefore compared the strain of Wistar rats with high susceptibility which we used frequently in our previous studies on lactotroph proliferation and the least susceptible strain WKY rats which have a genetic background close to Wistar rats. Using these two strains, we addressed the possibility that lack of pituitary growth response to long-term estrogen treatment in WKY rats is due to attenuation of the proliferative action and/or enhancement of the antiproliferative action of estrogen on lactotrophs as demonstrated in primary culture. There was no difference in the ability of 17-β estradiol (E2) to modulate lactotroph proliferation in vitro in Wistar and WKY rats. However, during the course of studying strain differences in the IGF-1-dependent anti-proliferative action of estrogen, we unexpectedly found that the proliferative action of IGF-1 was less potent in lactotrophs of WKY rats compared with Wistar rats.
Materials and Methods

Animals and treatment
The experiments were approved by the Ethical Committee of Animal Experiments of the University of Yamanashi. Eight-week-old female rats of the Wistar and WKY strains were purchased from Charles River Japan (Yokohama, Japan). In the in vivo experiments, the rats were injected sc with either 2 mg of estradiol valerate (EV; Progynon-Depot, Fuji Pharma, Toyama, Japan) or its vehicle sesame oil on the day of ovariectomy. At 0900 h 3 weeks after EV treatment, the animals were injected ip with 5-bromo-2'-deoxyuridine (BrdU; Sigma, St. Louis, MO, USA) at a dose of 50 mg/kg. Three hours after the BrdU injection, the animals were decapitated under diethyl ether anesthesia, and the anterior pituitary glands and uteri collected for measurement of wet weight. Uterine wet weight of EV-treated rats included the weight of intraluminal fluid if present. Individual anterior pituitaries were then dispersed enzymatically to determine the BrdU labeling index as described previously [25] .
Pituitary cell culture
Either 6 or 7 pituitaries obtained from ovary-intact WKY and Wistar rats were dispersed enzymatically morphogenetic protein 4 [16] . There is evidence that estrogens induce pituitary growth when pituitaries are transplanted under the kidney capsule [17] , and that intrapituitary implants of estrogen induce lactotroph hyperplasia in the ipsilateral lobe containing an estrogen implant but not in the contralateral lobe. These findings suggest that pituitary mechanisms play a dominant role in the action of estrogen on the development of PRL-secreting pituitary tumors [18] .
It is well known that there are differences in the susceptibility of rat strains to develop estrogen-induced pituitary tumors [19, 20] . Of the rat strains tested, the Fischer 344 (F344) strain is the most sensitive to this effect of administered estrogens. The high sensitivity group also includes the Wistar-Furth, ACI, Copenhagen, and Wistar strains, while the low sensitivity group includes the Sprague-Dawley (SD), Buffalo, and Holtzman strains with the Brown Norway strain being the least sensitive. Elias and Weiner [21] demonstrated that estrogen induced the development of a direct arterial blood supply to the anterior pituitary gland in F344 rats, but not in SD rats. This blood supply bypassed the inhibitory regulation of dopamine on lactotroph proliferation and suggested that the different susceptibility of rat strains to develop estrogen-induced pituitary tumors may be due to different responses of the pituitary vasculature to estrogens. However, it is probable that the difference in tumor susceptibility is inherent in pituitary cells themselves because estrogens induce pituitary growth when pituitaries are transplanted under the kidney capsule in F344 rats, but not in Holtzman rats [19] . Another possible mechanism for these strain differences may involve folliculo-stellate (FS) cells, which are pituitary non-hormone-secreting cells containing estrogen receptors that perform supportive functions including phagocytosis. FS cells show dramatic changes of phagocytotic activity after estrogen treatment in F344 rats, but not in SD rats [22] . Oomizu et al.
[23] demonstrated estrogen-stimulated proliferation of lactotrophs in cocultures of FS cells derived from F344 rats and lactotrophs derived from F344 or SD rats. However, this proliferation did not occur in cocultures of SD-derived FS cells and F344-derived lactotrophs. These findings suggest the involvement of paracrine communication between FS cells and lactotrophs that is mediated by basic fibroblast growth factor. However, the precise mechanism of strain differences in pituitary tumors induced by estrogen remains to be determined.
for each cell preparation as described previously [25] . A 100 µL aliquot of the cell suspension containing 2.0×10 5 pituitary cells was plated in poly-D-lysinecoated 35 mm culture dishes for the proliferation studies, and a 300 μL aliquot containing 6.0×10
5 pituitary cells plated for quantitative real-time PCR (qRT-PCR) analysis. The cells were allowed to attach to the surface of the dishes in a humidified CO 2 incubator for 1 h and were then flooded with 2 mL of a 1:1 mixture of Dulbecco's modified Eagle's medium (DMEM) and Ham's Nutrient Mix F-12 without phenol red containing 15 mM HEPES, penicillin, and streptomycin (DMEM/F12). The cells were pre-cultured at 37 °C in a humidified atmosphere of 5% CO 2 and 95% air for 1 day, washed with DMEM/F12, and then cultured in a serum-free, chemically-defined medium. The proliferative action of estrogen was studied by treating pituitary cells for 88 h with 1nM E2 (Sigma) or vehicle, ethanol (0.005%). An alternative means of inducing proliferation involved treating the cells for 40 h with either the vehicle or 10% dextran-coated charcoaltreated horse serum (DCC-HS) alone or in combination with 1nM E2. To study the anti-proliferative action of E2, the cells were treated for 40 h with either the vehicle or 30 ng/mL IGF-1 (Sigma) alone or in combination with 1nM E2. Proliferating cells in the cultures were labeled with 200 µM 5-bromo-2'-deoxyuridine (BrdU) (Sigma) for 3 or 16 h prior to the end of culture in the 40 and 88 h treatment experiments, respectively.
Immunostaining
To determine the BrdU-labeling index, pituitary cells labeled with BrdU were double-immunostained for BrdU and PRL as described previously [2] . The immunostained slides were examined using a fluorescence microscope equipped with a dual-band mirror unit for fluorescein isothiocyanate and Texas Red. A total of 1000 PRL-immunoreactive cells were examined in randomly chosen fields in each slide to determine the BrdU-labeling index, calculated as the percentage of cells immunoreactive for both PRL and BrdU in the total PRL-immunoreactive cell count.
Quantitative real-time PCR (qRT-PCR)
The expression levels of mRNAs for IGF-1-responsive genes were determined by qRT-PCR analysis as described previously [26] . The total RNAs were extracted as described earlier, and 1 μg aliquots reversetranscribed using the ReverTra Ace ® qPCR RT Kit (Toyobo, Osaka, Japan). The reverse transcriptase reactions were amplified on an ABI Prism 7500 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) using a SYBR Green Realtime PCR Master Mix (Toyobo). The sequences of the primers used for the qRT-PCR analyses were as follows: Ccnd1, forward 5'-AGTCTGCCCTGTGACATGAATG-3'; Ccnd1 reverse, 5'-AAGCGCCATGGTGTGTCAA-3'; Dhcr24 forward, 5'-CTTGGCTGCATGGTTCTCTGT-3'; Dhcr24 reverse, 5'-CCCTTTCAGCATCAGCCAAT-3'; Igf1 forward, 5'-CCGCTTCCTTCACAGAATCTAATAA-3'; Igf1 reverse, 5'-GAGGAGGCCAAATTCAACAAAT-3'. The sequences of the primers for the other genes have been described previously [26, 27] . The mRNA levels were calculated using the 2 -∆∆CT method, with acid ribosomal phosphoprotein P0 as the endogenous reference.
Statistical analysis
The experiments were carried out using three culture dishes per experimental group and replicated at least three times using separate batches of cell preparations unless otherwise stated. Differences between the groups were analyzed using two-way ANOVA, followed by Fisher's protected least significant difference test.
Results
Strain differences between WKY and Wistar rats in the induction of pituitary tumors by long-term EV treatment in vivo
We first addressed the validity of using the WKY and Wistar rats as models of low and high estrogen susceptibility, respectively. Three weeks after injection of 2 mg EV, pituitary weight increased 4.0-fold in ovariectomized Wistar rats (p<0.05), but did not increase significantly in ovariectomized WKY rats (Fig 1A) . The proliferation rates of lactotrophs in these pituitary tumors determined by the BrdU labeling index changed in parallel with pituitary weight. Lactotroph proliferation was increased 12-fold or more by EV treatment in Wistar rats compared with vehicle treatment (p<0.05). In contrast there was no significant increase in proliferation with EV treatment in WKY rats ( Fig  1B) . Uterine weight increased significantly following EV treatment in both strains compared with vehicle treatment (p<0.05), although the increase was significantly smaller in WKY rats compared with Wistar rats (p<0.05) (Fig 1C) .
Strain differences in lactotroph proliferation in primary culture between WKY and Wistar rats
The proliferation of lactotrophs in primary culture induced by estrogen is known to be dependent on cell culture conditions [28] . The proliferative action of E2 alone on lactotrophs only occurs after a long period of treatment. The duration of this period can be reduced by adding serum such as DCC-HS to the culture. In addition to its well known in vivo and in vitro proliferative actions, E2 exerts an anti-proliferative action on lactotrophs in the presence of growth factors such as IGF-1 and insulin via suppressing expression of the Bcl3 gene [27] . We therefore compared the proliferative and anti-proliferative actions of E2 on lactotrophs in primary culture obtained from WKY and Wistar rats. Treatment for 88 h with 1nM E2 alone caused a significant increase in basal proliferation levels of lactotrophs obtained from Wistar rats (p<0.05). A similar increase in proliferation was observed in lactotrophs from WKY rats (p<0.05) (Fig 2A) . Treatment for 40 h with 10% DCC-HS alone did not result in a significant increase in basal proliferation levels of lactotrophs from Wistar rats, whereas simultaneous treatment with 1nM E2 significantly increased proliferation (p<0.05) (Fig 2B) . Lactotrophs obtained from WKY rats also showed an increase in proliferation in response to E2 treatment in the presence of DCC-HS (p<0.05). Treatment for 40 h with 30 ng/mL IGF-1 markedly increased basal proliferation levels of lactotrophs from Wistar rats (p<0.05), with simultaneous treatment with E2 significantly lowering the high levels induced by IGF-1 (p<0.05) (Fig 2C) . The anti-proliferative action of E2 observed in the presence of IGF-1 also occurred in lactotrophs from WKY rats. The only strain difference observed between the Wistar and WKY cells was the degree of responsiveness of lactotroph proliferation to IGF-1, with this being attenuated in WKY cells (strain×treatment interaction was significant at p<0.
05).
To further analyze this strain difference in IGF-1 responsiveness, we compared the dose-response for IGF-1-induced proliferation of lactotrophs in the two strains of rats. IGF-1 at a dose of 0.3 ng/mL did not change basal proliferation levels in lactotrophs from Wistar rats, whereas higher doses of 3 and 30 ng/mL caused a significant increase in proliferation in a dose-dependent manner (p<0.05) (Fig 2D) . In contrast, lactotrophs of WKY rats showed a significantly attenuated proliferation at these two doses of IGF-1 (strain×treatment interaction was significant at p<0.05).
Strain differences in mRNA expression of IGF-1-responsive genes in pituitary cells in primary culture between WKY and Wistar rats
The (Fig 3) . The strain difference in mRNA expression between Wistar and WKY cells in response to IGF-1 treatment was dependent on the gene. mRNA expression induced by IGF-1 was similar in the two strains of rats for the upregulated genes Dhcr24, Ccnd1, Fosl1, and Nptx1, and the downregulated genes Igf1 and Giot1. However, in WKY cells, IGF-1-induced responses were significantly attenuated for the Wnt4 and Stc1 genes (p<0.05), and did not occur at all for the Mybl1 and Myc genes (p<0.05).
Discussion
This study confirmed that the anterior pituitary of WKY rats does not show any growth response to long-term estrogen treatment, which is known to cause pituitary tumors in rat strains with high estrogen-susceptibility. These results indicate that the WKY strain has low estrogen susceptibility similar to the Brown Norway strain, and is therefore a useful model for studying strain differences in the development of pituitary tumors induced by estrogen. Our in vivo studies showed that the absence of growth response of WKY pituitaries to estrogen was due mainly to a lack of lactotroph proliferation. We also investigated whether there were differences between the WKY and Wistar rats in the proliferative and/or anti-proliferative actions of estrogen on lactotrophs in primary culture. These studies demonstrated that the proliferative action of E2 alone or in combination of serum, and the anti-proliferative action of E2 in combination with IGF-1 were the same in lactotrophs from the two strains of rats. These findings suggest that the lack of proliferative responsiveness in vivo of lactotrophs to long-term estrogen treatment in WKY rats is not attributable to attenuation of the proliferative action and/or enhancement of the anti-proliferative action of estrogen in primary cultures. It is probable that the action of estrogen on lactotroph proliferation in cultured cells or with short-term treatment may differ greatly from that observed with long-term in vivo treatment in nature and action mechanism.
During the course of studying strain differences in the anti-proliferative action of estrogen, we unexpect- edly found that the proliferative action of IGF-1 was less potent in lactotrophs of WKY rats compared with Wistar rats. It remains to be determined whether this attenuated response of lactotroph proliferation to IGF-1 in cultured cells was responsible for the lack of proliferation of lactotrophs to long-term estrogen treatment observed in WKY rats. This possibility is supported by several lines of evidence suggesting that IGF-1 mediates the proliferative action of estrogen as an autocrine/paracrine factor: First, mRNA expression of the IGF-1 gene is stimulated in pituitary tumors caused by long-term estrogen treatment [29] . Second, it has been shown that there is an interaction between the estrogen and IGF-1 signaling pathways in the regulation of proliferation of several estrogen-responsive cells [30] . Blockade of the IGF-1 signaling pathway is known to abolish estrogeninduced proliferation in the uterus [31, 32] . It is therefore possible that the decreased capability of IGF-1 to stimulate lactotroph proliferation may be responsible for the lack of proliferative responsiveness of these cells to long-term estrogen treatment in WKY rats.
In accordance with the changes in the proliferative action of IGF-1, we found that mRNA expression of the Wnt4, Stc1, Mybl1, and Myc genes in response to IGF-1 was also attenuated or abolished in pituitary cells of WKY rats. Many of these genes are known to be involved in the regulation of normal cell proliferation and pathogenesis of cancer [33] [34] [35] . The strain difference between WKY and Wistar rats in the expression of these genes in response to IGF-1 in cultured cells may also be implicated in strain differences in the development of pituitary tumors induced by estrogen.
In addition to the anterior pituitary gland, the uterus showed a reduced growth response to EV treatment in WKY rats. To our knowledge, these results are the first to demonstrate a strain difference in the responsiveness of the uterus to estrogen. The strain difference observed in the uterine response was modest and not as marked as that in the pituitary response, and therefore the significance of the strain difference remains to be determined. Estrogens increase mRNA expression of IGF-1 and IGF-1 receptor [36, 37] and decrease IGF binding protein mRNA expression in the uterus [38] . Furthermore, it has been shown that the blockade of the IGF-1 signaling pathway inhibits estrogeninduced uterine proliferation [39, 40] . Taken together, these findings suggest that IGF-1is involved as an autocrine/paracine mediator of the proliferative action of estrogen in the uterus. Consequently, it is possible that the reduced response of uterine growth to estrogen in WKY rats is due to a reduced proliferative action of IGF-1 on the uterus, which is similar to but much less than that in pituitary lactotrophs.
In conclusion, we demonstrate that IGF-induced proliferation and gene expression is reduced in lactotrophs in primary culture of WKY rats. This feature may render lactotrophs insusceptible to the proliferative action in vivo of estrogen with long-term treatment in this strain.
